Axsome Therapeutics (AXSM) Accounts Payables (2015 - 2026)

Axsome Therapeutics has disclosed Accounts Payables across 12 years of filings, most recently posting $106.7 million for Q1 2026.

• Accounts Payables for Q1 2026 came in at $106.7 million, up 24.57% year-over-year; the trailing twelve-month figure through Mar 2026 was $106.7 million (up 24.57% YoY), and the FY2025 annual result was $65.5 million, down 55.71% from the prior year.
• Accounts Payables came in at $106.7 million for Q1 2026 at Axsome Therapeutics, up from $65.5 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $148.0 million in Q4 2024 to a low of $12.6 million in Q1 2022.
• The 5-year median for Accounts Payables is $64.3 million (2024), against an average of $66.5 million.
• Across the five-year window, Accounts Payables surged 510.79% in 2023 and tumbled 55.71% in 2025, its largest moves.
• Axsome Therapeutics' Accounts Payables stood at $51.6 million in 2022, then soared by 75.28% to $90.5 million in 2023, then soared by 63.52% to $148.0 million in 2024, then plunged by 55.71% to $65.5 million in 2025, then surged by 62.81% to $106.7 million in 2026.
• The last three Accounts Payables figures came in at $106.7 million (Q1 2026), $65.5 million (Q4 2025), and $54.2 million (Q3 2025), per Business Quant data.